CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Galectin Therapeutics Inc. - GALT CFD

2.3665
0.84%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0470
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Galectin Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.3865
Open* 2.3565
1-Year Change* 21.8%
Day's Range* 2.2665 - 2.3765
52 wk Range 1.08-2.47
Average Volume (10 days) 56.82K
Average Volume (3 months) 1.28M
Market Cap 107.62M
P/E Ratio -100.00K
Shares Outstanding 61.85M
Revenue N/A
EPS -0.76
Dividend (Yield %) N/A
Beta 0.80
Next Earnings Date Mar 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 2.3865 0.0900 3.92% 2.2965 2.4165 2.2965
Mar 26, 2024 2.3265 -0.0200 -0.85% 2.3465 2.3565 2.2365
Mar 25, 2024 2.3265 -0.1000 -4.12% 2.4265 2.4565 2.2765
Mar 22, 2024 2.4265 -0.0200 -0.82% 2.4465 2.4465 2.2965
Mar 21, 2024 2.3965 0.2000 9.11% 2.1965 2.4265 2.1965
Mar 20, 2024 2.1865 0.1300 6.32% 2.0565 2.1865 2.0565
Mar 19, 2024 2.0965 -0.0500 -2.33% 2.1465 2.1565 2.0765
Mar 18, 2024 2.1365 0.1100 5.43% 2.0265 2.1565 1.9765
Mar 15, 2024 2.0365 0.0600 3.04% 1.9765 2.0565 1.9465
Mar 14, 2024 1.9565 -0.0100 -0.51% 1.9665 1.9665 1.9065
Mar 13, 2024 1.9765 0.0700 3.67% 1.9065 2.0065 1.8765
Mar 12, 2024 1.9765 -0.0100 -0.50% 1.9865 2.0665 1.8865
Mar 11, 2024 2.0065 0.0200 1.01% 1.9865 2.0465 1.9665
Mar 8, 2024 2.0265 -0.0200 -0.98% 2.0465 2.0565 1.9865
Mar 7, 2024 2.0765 0.0300 1.47% 2.0465 2.0765 1.9765
Mar 6, 2024 2.0565 0.0500 2.49% 2.0065 2.0865 1.9765
Mar 5, 2024 2.0465 0.0800 4.07% 1.9665 2.0465 1.9565
Mar 4, 2024 1.9765 0.0500 2.60% 1.9265 1.9865 1.8765
Mar 1, 2024 1.9265 0.0300 1.58% 1.8965 2.0065 1.8765
Feb 29, 2024 1.9365 0.0400 2.11% 1.8965 1.9765 1.8965

Galectin Therapeutics Inc. Events

Time (UTC) Country Event
Monday, May 13, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Galectin Therapeutics Inc Earnings Release
Q1 2024 Galectin Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 38.352 30.179 23.444 13.438 13.602
Selling/General/Admin. Expenses, Total 6.615 6.361 5.468 5.971 7.131
Research & Development 31.737 23.818 17.976 7.467 6.471
Operating Income -38.352 -30.179 -23.444 -13.438 -13.602
Interest Income (Expense), Net Non-Operating -0.424 -0.348 -0.021 0.144 -0.298
Net Income Before Taxes -38.776 -30.527 -23.465 -13.294 -13.9
Net Income After Taxes -38.776 -30.527 -23.465 -13.294 -13.9
Net Income Before Extra. Items -38.776 -30.527 -23.465 -13.294 -13.9
Net Income -38.776 -30.527 -23.465 -13.294 -13.9
Total Adjustments to Net Income -0.097 -0.171 -0.137 -6.885 -1.147
Income Available to Common Excl. Extra. Items -38.873 -30.698 -23.602 -20.179 -15.047
Income Available to Common Incl. Extra. Items -38.873 -30.698 -23.602 -20.179 -15.047
Diluted Net Income -38.873 -30.698 -23.602 -20.179 -15.047
Diluted Weighted Average Shares 59.391 58.527 57.029 52.238 39.414
Diluted EPS Excluding Extraordinary Items -0.65453 -0.52451 -0.41386 -0.38629 -0.38177
Diluted Normalized EPS -0.65453 -0.52451 -0.41386 -0.38629 -0.38177
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 9.003 10.342 10.633 8.122 9.662
Selling/General/Admin. Expenses, Total 1.632 1.543 1.626 1.524 1.588
Research & Development 7.371 8.799 9.007 6.598 8.074
Operating Income -9.003 -10.342 -10.633 -8.122 -9.662
Interest Income (Expense), Net Non-Operating -0.111 -1.185 -0.001 -0.475 0.049
Net Income Before Taxes -9.114 -11.527 -10.634 -8.597 -9.613
Net Income After Taxes -9.114 -11.527 -10.634 -8.597 -9.613
Net Income Before Extra. Items -9.114 -11.527 -10.634 -8.597 -9.613
Net Income -9.114 -11.527 -10.634 -8.597 -9.613
Total Adjustments to Net Income -0.063 0 -0.065 0.016 -0.064
Income Available to Common Excl. Extra. Items -9.177 -11.527 -10.699 -8.581 -9.677
Income Available to Common Incl. Extra. Items -9.177 -11.527 -10.699 -8.581 -9.677
Diluted Net Income -9.177 -11.527 -10.699 -8.581 -9.677
Diluted Weighted Average Shares 59.582 59.48 59.424 59.396 59.389
Diluted EPS Excluding Extraordinary Items -0.15402 -0.1938 -0.18005 -0.14447 -0.16294
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.15402 -0.1938 -0.18005 -0.14447 -0.16294
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 20.552 41.82 29.465 48.209 8.832
Cash and Short Term Investments 18.592 39.648 27.142 47.48 8.253
Cash & Equivalents 18.592 39.648 27.142 47.48 8.253
Prepaid Expenses 1.96 2.172 2.323 0.729 0.579
Total Assets 21.285 41.827 29.6 48.467 9.006
Property/Plant/Equipment, Total - Net 0.086 0.007 0.048 0.084 0
Property/Plant/Equipment, Total - Gross 0.081 0.122 0.158 0.074
Accumulated Depreciation, Total -0.074 -0.074 -0.074 -0.074
Intangibles, Net 0
Total Current Liabilities 13.012 9.033 5.399 2.82 2.108
Accounts Payable 3.89 1.805 1.292 1.661 0.297
Accrued Expenses 9.058 7.163 4.042 1.093 1.512
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.064 0.065 0.065 0.066 0.299
Total Liabilities 53.479 39.211 5.407 2.872 2.108
Total Long Term Debt 39.828 29.048 0 0 0
Total Equity -32.194 2.616 24.193 45.595 6.898
Redeemable Preferred Stock 2.233 2.25 2.25 2.26 2.26
Preferred Stock - Non Redeemable, Net 6.682
Common Stock 0.059 0.059 0.056 0.056 0.041
Additional Paid-In Capital 275.081 271.001 261.883 259.673 194.13
Retained Earnings (Accumulated Deficit) -309.567 -270.694 -239.996 -216.394 -196.215
Total Liabilities & Shareholders’ Equity 21.285 41.827 29.6 48.467 9.006
Total Common Shares Outstanding 59.426 59.3413 57.0771 56.8946 41.1909
Total Preferred Shares Outstanding 1.26018 1.30268 1.30268 1.32768 6.83568
Other Long Term Assets, Total 0.647 0.087 0.174 0.174
Other Liabilities, Total 0.639 1.13 0.008 0.052
Long Term Debt 39.828 29.048
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 21.611 19.468 19.552 20.552 17.121
Cash and Short Term Investments 20.362 17.966 17.799 18.592 15.831
Cash & Equivalents 20.362 17.966 17.799 18.592 15.831
Prepaid Expenses 1.249 1.502 1.753 1.96 1.29
Total Assets 22.163 20.081 20.225 21.285 17.914
Property/Plant/Equipment, Total - Net 0.062 0.07 0.078 0.086 0.093
Other Long Term Assets, Total 0.49 0.543 0.595 0.647 0.7
Total Current Liabilities 10.522 9.953 11.533 13.012 9.588
Accounts Payable 2.681 1.976 2.553 3.89 2.352
Accrued Expenses 7.841 7.913 8.98 9.058 7.236
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 0.064 0 0.064 0
Total Liabilities 73.036 71.208 62.871 53.479 40.249
Total Long Term Debt 61.14 60.359 49.941 39.828 29.734
Other Liabilities, Total 1.374 0.896 1.397 0.639 0.927
Total Equity -50.873 -51.127 -42.646 -32.194 -22.335
Redeemable Preferred Stock 2.233 2.233 2.233 2.233 2.233
Common Stock 0.061 0.059 0.059 0.059 0.059
Additional Paid-In Capital 291.145 276.852 276.156 275.081 274.241
Retained Earnings (Accumulated Deficit) -344.312 -330.271 -321.094 -309.567 -298.868
Total Liabilities & Shareholders’ Equity 22.163 20.081 20.225 21.285 17.914
Total Common Shares Outstanding 61.8487 59.5822 59.5822 59.426 59.426
Total Preferred Shares Outstanding 1.26018 1.26018 1.26018 1.26018 1.26018
Long Term Debt 61.14 60.359 49.941 39.828 29.734
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -38.776 -30.527 -23.465 -13.294 -13.9
Cash From Operating Activities -31.056 -24.308 -20.601 -10.848 -10.179
Cash From Operating Activities 0
Non-Cash Items 2.752 2.468 1.922 1.805 4.793
Changes in Working Capital 4.968 3.751 0.942 0.641 -1.072
Cash From Investing Activities 0 0 0
Capital Expenditures 0
Cash From Financing Activities 10 36.814 0.263 50.075 15.379
Issuance (Retirement) of Stock, Net 0 6.814 0.263 50.469 15.379
Net Change in Cash -21.056 12.506 -20.338 39.227 5.2
Total Cash Dividends Paid 0 -0.394
Other Investing Cash Flow Items, Total 0 0
Issuance (Retirement) of Debt, Net 10 30
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -11.527 -38.776 -28.142 -19.545 -9.932
Cash From Operating Activities -10.793 -31.056 -23.817 -15.47 -8.042
Non-Cash Items 1.607 2.752 2.206 1.176 0.719
Changes in Working Capital -0.873 4.968 2.119 2.899 1.171
Cash From Financing Activities 10 10 0 0 0
Issuance (Retirement) of Stock, Net 0 0 0 0
Net Change in Cash -0.793 -21.056 -23.817 -15.47 -8.042
Issuance (Retirement) of Debt, Net 10 10 0 0
Cash From Investing Activities 0
Other Investing Cash Flow Items, Total 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Galectin Therapeutics Inc. Company profile

About Galectin Therapeutics Inc

Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 49% to $23.4M. Higher net loss reflects Research and development increase of 58% to $17.7M (expense), Other General and administrative increase of 15% to $3.6M (expense), Stock-based Compensation in SGA increase of 38% to $1.2M (expense).

Equity composition

Common Stock $.001 Par, 03/12, 300M auth., 12,842,850 issd. Insiders own 18.44%. Ser. A Pref. Stock 5M auth., 1,592,500 issd. Redeemable convt. Pref. stock Ser. B-1 900,000 auth., 900,000 issd. Ser. B-2 2.1M auth., 2,100,000 issd. PO 12/13/01, 1,428,572 shares @ $3.50by Atlas Capital Services LLC. 03/12. 1-for-6 Reverse split.

Industry: Biotechnology & Medical Research (NEC)

Suite 240
4960 Peachtree Industrial Boulevard
NORCROSS
GEORGIA 30071
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

US100

18,264.10 Price
+0.000% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

3,575.25 Price
+1.670% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

70,937.05 Price
+2.740% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,219.29 Price
+1.130% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading